2',3'-Dideoxyadenosine-5'-Triphosphate

default
N-4001
ddATP
-->
SKU Unit Size Price Qty
N-4001-1 1 µmole
$32.00
N-4001-5 5 µmole
$134.00
N-4001-10 10 µmole
$243.00
Request Bulk Pricing

Description

2',3'-Dideoxyadenosine-5'-Triphosphate (ddATP) is a sugar modified nucleoside triphosphate, where the 2' and 3' hydroxyl groups are absent, resulting in chain termination. The inability of polymerases to extend from a dideoxy nucleotide causes the chain termination and is widely useful in antiviral research and in a variety of biotechnology applications. ddATP is used in cycle sequencing, enzyme mechanistic studies and for producing RNA and DNA sequences that cannot be extended by polymerases or joined by DNA ligases. Another notable application that utilizes a primer terminated on the 3′ end with a dideoxy modification is pyrophosphorolysis-activated polymerization (PAP). This technique is valuable for the detection of rare mutations. "I use ddNTPs from TriLink for sequencing using DNA and RNA as templates and it always gives me good results." Michal Legiewicz Research Scientist Yale University

Product Details

Catalog No N-4001
Purity ≥95% by AX-HPLC
Extinction Coefficient 15,400 Lmol-1cm-1 at 258 nm
Molecular Formula C10H16N5O11P3 (free acid)
Molecular Weight 475.10 g/mole (free acid)
Salt Form Li+
Concentration 100 mM
Buffer H2O
Recommended Storage -20°C or below
Other Name(s) ddATP
Application Aptamers
Backbone 5'-Triphosphate
Base Analog(s) Adenosine
Nucleotide Category Sugar Modified

Technical Documents




Intellectual Property

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission of Seller. No license under any patent or other intellectual property right of Seller or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.



References

Saint, Cecile Le; Terreux, Raphael; Duval, Daniele; Durant, Jacques; Ettesse, Helene; Dellamonica, Pierre; Guedj, Roger; Vincent, Jean Pierre; Cupo, Anny . Determination of ddATP Levels in Human Immunodeficiency Virus-Infected Patients Treated with Dideoxyinosine

Vooradi, Venkataramana; Romano, Louis J. . Effect ofN-2-Acetylaminofluorene and 2-Aminofluorene Adducts on DNA Binding and Synthesis by Yeast DNA Polymerase

Sahu, Sudheer; LaBean, Thomas H.; Reif, John H. . A DNA Nanotransport Device Powered by Polymerase 29

Mizrahi, Rena A.; Schirle, Nicole T.; Beal, Peter A. . Potent and Selective Inhibition of A-to-I RNA Editing with 2′-O-Methyl/Locked Nucleic Acid-Containing Antisense Oligoribonucleotides

Smith, Thomas M.; Lim, Siew Pheng; Yue, Kimberley; Busby, Scott A.; Arora, Rishi; Seh, Cheah Chen; Wright, S. Kirk; Nutiu, Razvan; Niyomrattanakit, Pornwaratt; Wan, Kah Fei; Beer, David; Shi, Pei-Yong; Benson, Timothy E. . Identifying initiation and elongation inhibitors of dengue virus RNA polymerase in a high-throughput lead-finding campaign.

Ordonez, Paula; Kunzelmann, Simone; Groom, Harriet C. T.; Yap, Melvyn W.; Weising, Simon; Meier, Chris; Bishop, Kate N.; Taylor, Ian A.; Stoye, Jonathan P. . SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells.

Contreras-Galindo, Rafael; Dube, Derek; Fujinaga, Koh; Kaplan, Mark H.; Markovitz, David M. . Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.

Su, Kang-Yi; Lai, Hung-Ming; Goodman, Steven D.; Hu, Wei-Yao; Cheng, Wern-Cherng; Lin, Liang-In; Yang, Ya-Chien; Fang, Woei-Horng . Application of single nucleotide extension and MALDI-TOF mass spectrometry in proofreading and DNA repair assay.